drugset / Trial / NCT04385654
Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of toripalimab combined with axitinib as neoadjuvant therapy for advanced/metastatic non-clear cell renal cell carcinoma
Timeline
- Start
- 2020-06
- Primary completion
- 2021-12
- Completion
- 2022-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |